June 11, 2025

8-Week Oral Therapy Approved for Acute HCV

The FDA has approved Mavyret for the treatment of acute hepatitis C, offering physicians a pangenotypic, 8-week oral regimen for early intervention.

Conexiant

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 05, 2025

Risky College Behaviors Harming Oral Health?

First-year university students who adopted unhealthy habits such as poor diet, vaping, and reduced brushing frequency experienced significant declines in self-reported oral health over 6 months.

Conexiant

June 04, 2025

Does Sleep Duration Shape Oral Microbiomes?

New research reveals positive association between extended sleep duration and higher oral microbiome diversity in adolescents and young adults.

Conexiant

June 04, 2025

New Guidelines Recommend Hypnotherapy, CBT for Pediatric Abdominal Pain

Joint ESPGHAN/NASPGHAN guidance outlines evidence-based treatments for functional abdominal pain and irritable bowel syndrome in pediatric patients.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 20, 2025

New Noninvasive Option for Functional Abdominal Pain

The FDA has cleared IB-Stim as the first treatment specifically indicated for pediatric functional dyspepsia and related nausea, providing a noninvasive neuromodulation option for abdominal pain in patients aged 8 to 21 years.

Conexiant